Nerandomilast Patent Expiration

Nerandomilast was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Jascayd on Oct 7, 2025.


Nerandomilast Patents

Given below is the list of patents protecting Nerandomilast, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Jascayd US11406638 Oct 22, 2038 Boehringer Ingelheim
Jascayd US11813266 Oct 22, 2038 Boehringer Ingelheim
Jascayd US9802954 Feb 19, 2034 Boehringer Ingelheim
Jascayd US8609670 Aug 23, 2032 Boehringer Ingelheim
Jascayd US8754073 Nov 26, 2029 Boehringer Ingelheim



Nerandomilast's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Nerandomilast Generic API Manufacturers

Given below is the list of companies who have filed for Nerandomilast generic, along with the locations of their manufacturing plants worldwide.